Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment
Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment
About this item
Full title
Author / Creator
Publisher
United States: U.S. National Center for Infectious Diseases
Journal title
Language
English
Formats
Publication information
Publisher
United States: U.S. National Center for Infectious Diseases
Subjects
More information
Scope and Contents
Contents
High-dose isoniazid is recommended to treat multidrug-resistant tuberculosis (MDR TB). Among 958 MDR TB isolates identified in France during 2008-2022, 93.1% exhibited high-level isoniazid resistance, and molecular testing showed limited diagnostic accuracy in predicting resistance. Clinicians should reconsider using high-dose isoniazid in MDR TB t...
Alternative Titles
Full title
Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_6ae401a40fc0404b9a655750dc0459c5
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_6ae401a40fc0404b9a655750dc0459c5
Other Identifiers
ISSN
1080-6040,1080-6059
E-ISSN
1080-6059
DOI
10.3201/eid3103.241473
